N1-([3,3']-bipyridin-5-ylmethyl)-N1-methylethane-1,2-diamine | 484671-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N1-([3,3']-bipyridin-5-ylmethyl)-N1-methylethane-1,2-diamine
• 英文别名: N1-[3,3']bipyridinyl-5-ylmethyl-N1-methylethane-1,2-diamine；N1-[3,3']Bipyridinyl-5-ylmethyl-N1-methyl-ethane-1,2-diamine；N'-methyl-N'-[(5-pyridin-3-ylpyridin-3-yl)methyl]ethane-1,2-diamine
• CAS: 484671-46-7
• 化学式: C₁₄H₁₈N₄
• 分子量: 242.324
• InChiKey: AYAOOWNQJDHKCT-UHFFFAOYSA-N

物化性质

• 沸点：
  387.2±37.0 °C(Predicted)
• 密度：
  1.111±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N1-([3,3']-bipyridin-5-ylmethyl)-N1-methylethane-1,2-diamine 在 甲醇 作用下， 以 水 、 乙腈 为溶剂， 反应 28.0h， 生成 (3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-1-{2-[(3,3'-bipyridin-5-ylmethyl)(methyl)amino]ethyl}-4-ethyl-11-methoxy-7,9,11,13,15-pentamethyl-2,6,8,14-tetraoxo-3a-vinyltetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl-3,4,6-trideoxy-3-(dimethylamino)-D-xylo-hexopyranoside
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel C₁₂ Vinyl Ketolides

  摘要：

  A novel series Of C-12 vinyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens. The C-12 modification involves replacing the natural C-12 methyl group in the erythromycin core with a vinyl group via chemical synthesis. From the C-12 vinyl macrolide core, a series Of C-12 vinyl ketolides was prepared. Several compounds were found to be potent against macrolide-sensitive and -resistant bacteria. The C-12 vinyl ketolides 6j and 6k showed a similar antimicrobial spectrum and comparable activity to the commercial ketolide telithromycin. However, the pharmacokinetic profiles Of C-12 vinyl ketolides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, larger volumes of distribution, and longer half-lives. These pharmacokinetic differences have a pharmacodynamic effect as both 6j and 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Streptococcus pneumoniae and Haemophilus influenzae.

  DOI：

  10.1021/jm051157a
• 作为产物：
  描述：

  二乙基(3-吡啶基)-硼烷 在 sodium tetrahydroborate 、 四(三苯基膦)钯 、 草酰氯 、 三乙酰氧基硼氢化钠 、 potassium carbonate 、 溶剂黄146 、 二甲基亚砜 、 三乙胺 、 肼 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 112.0h， 生成 N1-([3,3']-bipyridin-5-ylmethyl)-N1-methylethane-1,2-diamine
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel C₁₂ Vinyl Ketolides

  摘要：

  A novel series Of C-12 vinyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens. The C-12 modification involves replacing the natural C-12 methyl group in the erythromycin core with a vinyl group via chemical synthesis. From the C-12 vinyl macrolide core, a series Of C-12 vinyl ketolides was prepared. Several compounds were found to be potent against macrolide-sensitive and -resistant bacteria. The C-12 vinyl ketolides 6j and 6k showed a similar antimicrobial spectrum and comparable activity to the commercial ketolide telithromycin. However, the pharmacokinetic profiles Of C-12 vinyl ketolides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, larger volumes of distribution, and longer half-lives. These pharmacokinetic differences have a pharmacodynamic effect as both 6j and 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Streptococcus pneumoniae and Haemophilus influenzae.

  DOI：

  10.1021/jm051157a

文献信息

• C12 Modified erythromycin macrolides and ketolides having antibacterial activity
  申请人：——

  公开号：US20030125266A1

  公开（公告）日：2003-07-03

  Antimicrobial macrolide compounds are provided having formulas II: 1 as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供具有II:1式的抗微生物大环内酯化合物，以及其药用盐、酯或前药；包含这类化合物的药物组合物；通过给予这类化合物治疗细菌感染的方法；以及这类化合物的制备方法。
• Synthesis and antibacterial activity of novel C12 ethyl ketolides
  作者：Matthew T. Burger、Christy Hiebert、Mehran Seid、Daniel T. Chu、Lynn Barker、Mike Langhorne、Ribhi Shawar、Jolene Kidney、Manoj C. Desai、Jacob J. Plattner

  DOI：10.1016/j.bmc.2006.04.032

  日期：2006.8

  A novel series of C(12) ethyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens, including those resistant to erythromycin. The C(12) modification involves replacing the natural C(12) methyl group in the erythromycin core with an ethyl group via chemical synthesis. From the C(12) ethyl macrolide core, a series of C(12) ethyl ketolides

  已经发现了一系列新的C（12）乙基红霉素衍生物，它们对关键的呼吸道病原体（包括对红霉素有抗性的病原体）表现出体外和体内效力。C（12）修改涉及通过化学合成用乙基取代红霉素核心中的天然C（12）甲基。从C（12）乙基大环内酯核心制备了一系列C（12）乙基酮缩酮，并测试了其对一组相关临床分离株的抗菌活性。无论是由于核糖体甲基化（erm）还是外排（mef），都发现了几种对大环内酯类敏感和耐药菌有效的化合物。特别是，C（12）乙基酮缩酮4k，4s，4q，4m和4t具有相似的抗菌谱，并且具有与商业酮内酯telithromycin相当的活性。
• C12 modified erythromycin macrolides and ketolides having antibacterial activity
  申请人：Chiron Corporation

  公开号：US06756359B2

  公开（公告）日：2004-06-29

  Antimicrobial macrolide compounds are provided having formulas II: as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  本发明提供具有II式的抗微生物大环内酯化合物，以及其药学上可接受的盐、酯或前药；包含这些化合物的药物组合物；通过给予这些化合物的途径治疗细菌感染的方法；以及制备这些化合物的过程。
• US6756359B2
  申请人：——

  公开号：US6756359B2

  公开（公告）日：2004-06-29
• US7332476B2
  申请人：——

  公开号：US7332476B2

  公开（公告）日：2008-02-19